Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	265.43	269.57	519.27	1,323	286.93	291.14
Short-Term Investments	7.3	7.3	148.42	16.12	-	-
Cash & Short-Term Investments	272.73	276.87	667.69	1,339	286.93	291.14
Cash Growth	6.19%	-58.53%	-50.15%	366.84%	-1.45%	5.02%
Accounts Receivable	85.02	140.74	58.53	81.32	320.84	169.03
Other Receivables	4.24	7.73	4.69	3.09	11.33	5.51
Receivables	89.25	148.47	63.22	84.41	332.17	174.54
Inventory	66.86	64.94	112.33	246.72	173.3	84.85
Prepaid Expenses	75.12	71.45	83.25	103.22	89.28	23.82
Other Current Assets	209.61	174.66	171.53	149.95	15.73	2.16
Total Current Assets	713.57	736.38	1,098	1,924	897.41	576.51
Property, Plant & Equipment	1,679	1,705	1,847	1,978	1,351	786.73
Long-Term Investments	171.66	177.87	190.81	199.51	109.59	191.81
Goodwill	23.92	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	10.36	12.34	18.98	25.93	33.71	36.72
Long-Term Deferred Tax Assets	99.63	98.6	95.49	89.72	81.11	83.45
Other Long-Term Assets	641.68	614.67	495.85	211.93	642.46	53.41
Total Assets	3,339	3,368	3,770	4,453	3,139	1,753
Accounts Payable	37.66	34.63	44.05	52.52	54.68	40.31
Accrued Expenses	79.55	98.05	112.32	104.21	96.4	66.6
Short-Term Debt	100	-	-	100	50	100
Current Portion of Long-Term Debt	196.55	168.08	125.92	105.88	15.6	-
Current Portion of Leases	31.78	31.92	30.57	37.28	28.59	24.33
Current Income Taxes Payable	-	-	-	-	-	0.65
Current Unearned Revenue	273.1	230.85	187.28	142.28	152.12	125.9
Other Current Liabilities	60.99	97.97	253.28	92.57	142.69	66.99
Total Current Liabilities	779.63	661.5	753.42	634.73	540.07	424.78
Long-Term Debt	581.09	611.37	530.4	656.32	474.4	-
Long-Term Leases	81.18	72.04	39.39	56.37	176.06	72.28
Long-Term Deferred Tax Liabilities	-	-	-	-	3.75	6.68
Other Long-Term Liabilities	-	-	-	-	38.07	37.14
Total Liabilities	1,442	1,345	1,323	1,347	1,232	540.89
Common Stock	2,071	2,070	2,059	2,053	1,533	1,282
Additional Paid-In Capital	423.33	421.11	1,074	1,468	576.95	53.11
Retained Earnings	-596.04	-466.91	-682.64	-406.83	-254.34	-207.23
Comprehensive Income & Other	-0.88	-0.79	-3.32	-8.8	50.72	83.41
Shareholders' Equity	1,898	2,023	2,447	3,106	1,907	1,212
Total Liabilities & Equity	3,339	3,368	3,770	4,453	3,139	1,753
Total Debt	990.59	883.39	726.28	955.85	744.64	196.61
Net Cash (Debt)	-717.87	-606.53	-58.59	383.63	-457.72	94.53
Net Cash Growth	-	-	-	-	-	-58.98%
Net Cash Per Share	-3.48	-2.94	-0.29	2.32	-3.08	0.73
Filing Date Shares Outstanding	207.11	207.01	205.89	205.31	153.33	128.24
Total Common Shares Outstanding	207.11	207.01	205.89	205.31	153.33	128.24
Working Capital	-66.05	74.89	344.59	1,289	357.34	151.73
Book Value Per Share	9.16	9.77	11.89	15.13	12.43	9.45
Tangible Book Value	1,863	1,987	2,404	3,056	1,849	1,151
Tangible Book Value Per Share	9.00	9.60	11.68	14.88	12.06	8.98
Buildings	792.86	792.86	792.86	791.68	-	-
Machinery	1,595	1,594	1,603	1,575	837.57	688.02
Construction In Progress	181.39	158.09	106.85	3.35	624.35	260.37
Leasehold Improvements	325.53	325.53	317.34	307.77	276.23	246.21

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.